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Linkage studies have implicated 10q22-q23 as a schizophrenia (SZ) susceptibility locus in Ashkenazi Jewish (AJ) and Han Chinese from
Taiwan populations. To further explore our previous linkage signal in the AJ population (NPL score: 4.27, empirical p ¼ 2 3 105), we
performed a peakwide association ﬁne mapping study by using 1414 SNPs across ~12.5 Mb in 10q22-q23. We genotyped 1515 AJ indi-
viduals, including 285 parent-child trios, 173 unrelated cases, and 487 unrelated controls. We analyzed the binary diagnostic phenotype
of SZ and 9 heritable quantitative traits derived from a principal components factor analysis of 73 items from our consensus diagnostic
ratings and direct assessment interviews. Although no marker withstood multiple test correction for association with the binary SZ
phenotype, we found strong evidence of association by using the ‘‘delusion’’ factor as the quantitative trait at three SNPs
(rs10883866, rs10748842, and rs6584400) located in a 13 kb interval in intron 1 of Neuregulin 3 (NRG3). Our best p value from
family-based association analysis was 7.26 3 107. We replicated this association in the collection of 173 unrelated AJ cases (p ¼ 1.55 3
102), with a combined p value of 2.30 3 107. After performing 10,000 permutations of each of the phenotypes, we estimated the
empirical study-wide signiﬁcance across all 9 factors (90,000 permutations) to be p ¼ 2.7 3 103. NRG3 is primarily expressed in the
central nervous system and is one of three paralogs of NRG1, a gene strongly implicated in SZ. These biological properties together
with our linkage and association results strongly support NRG3 as a gene involved in SZ.Introduction
Schizophrenia and schizoaffective disorder (MIM
#181500), which are hereafter referred to as ‘‘SZ,’’ consti-
tute a common and debilitating disorder affecting ~1% of
the population worldwide.1 Although the causes of SZ
are still unknown, multiple lines of evidence, including
twin, adoption, and family studies, suggest a strong genetic
component,2–4 most likely with extensive genetic hetero-
geneity.5 More than 20 genome-wide linkage scans and
numerous candidate gene/region-based association
studies6–10 have been performed to identify susceptibility
genes for SZ. Associations between SZ and a few candidate
genes (e.g., NRG1 [MIM *142445], DTNBP1 [MIM
*607145], andDISC1 [MIM *605210]) have been replicated
in various samples, but, aside from a translocation disrupt-
ing DISC1,11 no speciﬁc genetic alteration has convinc-
ingly been demonstrated as a causative variant.
Despite the availability of criteria for reliablediagnosis, SZ
is a clinically heterogeneous disorder.12–14 The extent to
which the phenotypic variability of SZ reﬂects underlying
genetic heterogeneity is uncertain.With the goal of charac-
terizing a more homogeneous phenotype(s), investigators
have attempted to delineate SZ subgroups according to
distinct clinical features, endophenotypes, and/or statisti-
callyderivedmeasures.14Accordingly,manygenetic studies
have been performed with SZ symptom dimensions,
subtypes, or endophenotypes as the disease variable(s).15–21TheOur previous genome-wide linkage analysis of SZ in the
Ashkenazi Jewish (AJ) population was the ﬁrst report of
a signiﬁcant linkage peak (NPL score ¼ 4.27, p ¼ 2 3
105) on chromosome 10q22-q23.22 Subsequently, an
independent linkage study based on 1234 affected
members in 606 Han Chinese families from Taiwan repli-
cated this linkage signal.23 Also, microdeletions in this
region have been associated with neuropsychiatric abnor-
malities.24 At least two biological candidates, GRID1
(Glutamate receptor, ionotropic, delta 1, [MIM *610659])
and NRG3 (MIM *605533), located under our linkage
peak have been implicated by association studies. Recent
candidate gene-based studies in AJ and Han Chinese pop-
ulations reported association between SZ and GRID1,25,26
whereas in a northern European sample, Benzel et al.
found nominal association signals for SZ with NRG3 (as
well as NRG1 and NRG2 [MIM *603818]) that were not
of sufﬁcient magnitude to withstand multiple testing
correction.27
To survey the 10q22-q23 interval for the source of our
linkage signal, we conducted a peakwide ﬁne mapping
association study by genotyping 1414 SNPs across the
12.5 Mb region in our AJ patients, parents, and unrelated
controls. The phenotypes for analysis included the binary
disease status (affected, not affected) and nine quantitative
traits or factors, derived from a principal components
factor analysis of 73 items from our consensus diagnostic
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Table 1. Nine Factors
Factor Name Main Phenotype Characteristics for Each Factor
Prodromal prodromal role impairment; prodromal lack of interest, energy; prodromal social isolation/withdrawal; prodromal impaired
hygiene; prodromal odd beliefs/magical thinking; prodromal peculiar behavior; prodromal unusual perceptions; premorbid
personality disorder; gradual onset of disorder (greater than 3 months)
Negative alogia; flat affect; negative formal thought disorder; apathy; anhedonia; poor adult sociality; failure to establish adult
independence
Delusion thought insertion; delusions of influence; somatic hallucinations; thought withdrawal; thought broadcasting; thought echo;
primary delusions; olfactory hallucinations; primary delusional perception; delusions of reference; delusions of guilt;
nihilistic delusions
Affective affective symptoms early in course; major depression criterion A; mania criterion A; self-damaging acts; affective syndrome
(in psychotic illness)
Scholastic poor high school adaptation; poor high school performance; none college; poor elementary school performance; learning
disability/hyperactivity; therapeutic school attendance; school deterioration
Child/Adolescent
Sociability
poor childhood sociability; poor childhood peer relations; poor adolescent sociability; poor adolescent peer relations; poor
elementary school adaptation
Disorganization incoherence/loose associations; bizarre behavior; inappropriate affect; self-neglect; poor insight; grandiose delusions;
committed assault; persecutory delusions; akathisia; Parkinsonian signs; does not meet criterion A for generalized anxiety
disorder; does not meet criterion A for obsessive-compulsive disorder; does not meet criterion A for panic disorder
Disability/Impairment history of occupational deterioration; occupational disability at time of diagnosis; history of occupational impairment; lives
alone instead of with family/friends; severe psychotic disorder; tardive dyskinesia; inconsistent, rare, or conflicted intimate
relationships; nonremitting course
Hallucination visual hallucinations; auditory hallucinations; tactile hallucinations; catatonic behavior; seizures; abnormal birth or early
development; affective syndrome not prominent, or postdates psychosis, or at least 1 week of psychosis occurred in absence
of affective symptomssignal achieved signiﬁcance for SZ disease status, we ﬁnd
strong evidence that three nearby SNPs in intron 1 of
NRG3 are associated with the ‘‘delusion’’ factor of SZ. In
addition, several SNPs in other parts of NRG3 show sugges-
tive association signals with other SZ factors.
Subjects and Methods
Ascertainment of Study Subjects
We recruited SZ individuals and controls of Ashkenazi descent in
North America via advertisements in newspapers and Jewish
newsletters, talks to community organizations, letters to leaders
of the Jewish community, letters and talks to service providers,
and a study website hosted by the Johns Hopkins Epidemiology-
Genetics Program in Psychiatry.22 We determined the ethnicity
of all four grandparents of cases and controls on the basis of
geographic origin and excluded those with non-Ashkenazi grand-
parents from our analysis. We considered individuals with grand-
parents from Spain, Netherlands, Turkey, or Greece as likely being
of Sephardic origin and also excluded any with self-reported
Sephardic heritage. Controls were also excluded if they screened
positive for a history of psychosis, mania, psychiatric hospitaliza-
tion, depression, or suicide attempt. Cases were recruited if they
met criteria for a diagnosis of SZ according to the Diagnostic and
Statistical Manual of Mental Disorders, 4th edition (DSM-IV).29
Case-parent trios were eligible for inclusion in these analyses if
the probands met the diagnostic criteria and both parents were
available for DNA collection. All recruitment methods and proto-
cols for collection of clinical data and blood samples were
approved by the Johns Hopkins institutional review board and
informed consent was obtained from all individuals.
Diagnostic Instruments and Procedures
All cases were examined in person by a clinical psychologist. Trio
parents were not examined but were asked for a blood sample.22 The American Journal of Human Genetics 84, 21–34, January 9, 2Most of the subjects were seen in their homes. Examiners used
the Diagnostic Interview for Genetic Studies (DIGS, version 2.0;
revised for DSM-IV), a semistructured interview that elicits infor-
mation about lifetime history of psychiatric symptoms and behav-
iors. On average, the subjects had been affected for 20.9 5 10.8
years at the time of the examination (minimum of 1, maximum
of 63). Thus, the item scores represent a compilation of all features
over an average of two decades. The subjects were asked to sign
release forms allowing us to receive copies of their psychiatric
records. Interviews were tape-recorded for quality control
purposes and for review by members of a consensus diagnosis
committee. Detailed clinical methods are available from our prior
publication.22
Factor Analysis and the Use of Factors as Quantitative
Traits for Association Study
To reﬁne our phenotypic characterization of individuals with SZ,
we took advantage of the detailed clinical information from our
standardized and comprehensive interviews.We performed a prin-
ciple components factor analysis on 73 items and derived 9 factors
best summarizing the clinical symptom dimensions. The proce-
dures and results are described in detail elsewhere.28 In brief, prin-
cipal components factor analysis was conducted in a sample of
1199 SZ subjects (including all the cases in this AJ collection and
other cases in an outbred northern European population) with
73 dichotomous signs and symptoms (Table 1) from consensus
diagnostic ratings, DIGS, and the Premorbid Adjustment Scale.30
Information on these signs and symptoms was not collected in
our controls. Parallel analyses and Velicer’s minimum average
partial correlation test provided statistical support for a solution
of from 8 to 15 factors. After testing this range, we obtained
a reasonable solution of 9 factors (designated prodromal, negative,
delusion, affective, scholastic, child/adolescent sociability, disor-
ganization, disability/impairment, and hallucination) (Table 1).
We transformed the factor scores to achieve normality with either
generalized modulus power transformations31 or natural log009
transformation28 and used the transformed factor scores as quan-
titative traits for family-based and unrelated case-only association
analyses.
Demographic and Clinical Characteristics
We genotyped a total of 1515 individuals, including 458 SZ
probands, 570 parents of schizophrenics, and 487 unrelated
controls (Figure 1).With SZ disease status as the binary phenotype,
we analyzed this data set as 285 independent parent-child trios for
family-based study and as 173 cases and 487 controls for an inde-
pendent case-control study to test for replication of the primary
signal in our family-based analysis. We also report an analysis of
all 458 cases and 487 controls with the caveat that 285 of the cases
overlap with the family-based analysis so that these two results are
not independent. When we used the nine factors as quantitative
traits, we did not include the controls because factor scores are
available only for cases. In that scenario, our data set was analyzed
as 285 parent-child trios for the family-based study and 173 unre-
lated SZ cases that serve as a replication case-only data set.
Of the 285 trio probands, the average age at onset was 19.5
(54.36) years, 74.3% of them were male, and 19.7% of them
were diagnosed as having schizoaffective disorder. Of the 173
unrelated cases, the average age at onset was 21.0 (56.46) years,
60.7% were male, and 21.4% were diagnosed as having schizoaf-
fective disorder. Of all the 487 AJ controls, 45.6% were male.
SNP Selection
By using publicly available information from dbSNP build 124,
NCBI genome build 35.1, and the HapMap project32,33 public
release #16c.1, we selected 1536 SNPs across the 95% conﬁdence
interval of our previous linkage peak at 10q22-q23, which was
a ~12.5 Mb region (chr10:79,550,189-92,037,551). We selected
Figure 1. AJ Individuals Enrolled in This Study
For analyses with SZ as a binary phenotype, the subjects for various
scenarios are: ‘‘Trios,’’ (a)þ(b); ‘‘CC-all’’ (case-control analysis with
all SZ individuals), (b)þ(c)þ(d); ‘‘Combined’’ (all samples),
(a)þ(b)þ(c)þ(d). For analyses with factors as quantitative traits,
the subjects for various scenarios are: ‘‘Trios,’’ (a)þ(b); ‘‘Cases-all’’
(case-only analysis with all SZ individuals), (b)þ(c); ‘‘Cases-inde-
pendent’’ (case-only analysis with independent SZ individuals),
(c); ‘‘Combined’’ (all SZ individuals and trios parents),
(a)þ(b)þ(c).The Athe SNPs in an iterative set of interactions with Illumina (Illumina
Corp, CA). An Illumina algorithm that predicted performance on
their genotyping platform was used to evaluate the SNPs. Initially,
we considered all dbSNPs in the interval (9911 at the time) and ob-
tained their Illumina scores. We discarded those with low scores
(<0.4, 628 SNPs) and then selected SNPs based on the following
criteria: (1) known minor allele frequency (MAF) > 0.05; (2)
submission to dbSNP frommore than one source; (3) validation re-
ported; (4) uniform distribution across the region; (5) a >60 base-
pairs interval from neighboring SNPs; and (6) a priority given to
those with a score >0.8. To ensure an unbiased coverage of the
whole region, we did not consider gene location in our initial
SNP selection. We then added nonsynonymous coding SNPs and
then SNPs to ﬁll coverage gaps. There are two segmental duplica-
tions in our region (approximately at chr10:80,900,000-
81,670,000 and chr10:88,880,000-89,170,000) (also see Figure 2)
in which we did not achieve good SNP coverage. Aside from these
two segmental duplications, the mean distance between two
consecutive SNPs is 7.85 (55.41) kb and the median distance
between two consecutive SNPs is 7.75 kb. The genotyped SNPs
and their location are provided in Table S1 available online.
Genotyping and Data Quality Control
Genotyping was performed with the Integrated BeadArray System
(Illumina Corp) at the Johns Hopkins Center for Inherited Disease
Research (CIDR). We supplied CIDR with 96-well barcoded micro-
titer plates containing genomic DNA samples (including 80
control samples from Centre d’Etude du Polymorphisme Humain
[CEPH]34 and 40 blind duplicates for quality control) at a concen-
tration of 125 ng/mL. Among the 1536 SNPs, 1498 had good
quality and were released for analysis. Of these 1498 SNPs, geno-
typing quality was excellent with an accuracy rate of 99.99%based
on blind duplications, a genotype missing rate of 0.09%, and
a Mendelian consistency rate of 99.99%. After removing SNPs
that were not polymorphic in our sample, there remained for asso-
ciation analysis a total of 1414 SNPs distributed over our 12.5 Mb
region.
Statistical Analyses
We use UNPHASED v3.0.9 for family-based, case-control, and
quantitative trait association analyses.35,36 The software is a versa-
tile application that can deal with binary phenotypes and quanti-
tative traits and can perform both allelic and genotypic tests.
Furthermore, in addition to dealing with familial and unrelated
samples separately, UNPHASED can perform a combined analysis
on a collection including both familial and unrelated samples,
with results presented in this report as the ‘‘combined p value.’’
We consider the allelic test of 285 trios to be our primary statistical
analysis, and the set of unrelated 173 cases to serve as an indepen-
dent sample for replication. When appropriate, we also report the
results of the analysis from ‘‘all cases’’ (285 familial plus 173 unre-
lated, totaling 458) and ‘‘all samples’’ (all 458 cases plus 570
parents and 487 unrelated controls) (see Figure 1). For the stron-
gest association signals detected in the allelic test, we also per-
formed and report the genotypic test. When SZ was used as the
binary phenotype, the analyses were a classical transmission
disequilibrium test (TDT),37 a case-control study, and a combined
analysis. When factors were used as the quantitative traits, the
unrelated controls were not included for analysis because factor
scores are available only in SZ cases. Therefore, the results reportedmerican Journal of Human Genetics 84, 21–34, January 9, 2009 23
Figure 2. Results of Association Analyses and Genes in the ~12.5 Mb Region at Chromosome 10q22-q23
The horizontal axis is the sequence position (chr10:79,550,189-92,037,551) according to NCBI genome build 35.1.
(A) Results with SZ as a binary phenotype. Values along the vertical axis are the negative logarithm (based 10) of the p values. CC-all,
case-control study of all cases and all controls. Subjects analyzed in various scenarios are described in Figure 1.
(B) Results with the nine factors as the quantitative traits. For clarity, we did not assign different colors to different factors. The
upper horizontal pink line marks the study-wide significance cutoff value for Bonferroni correction of all 1414 SNPs and all 9 factors24 The American Journal of Human Genetics 84, 21–34, January 9, 2009
Figure 3. Representative Quantile-Quantile Plots Based on 10,000 Permutations
The values plotted are the negative logarithm (based 10) of p values, either of the observed results (vertical axis) or the permutation
results (horizontal axis) of the corresponding phenotypes. The three lines in each plot represent the 97.5, 50, and 2.5 percentile values
of the permutation. The area between the upper line and lower line represents the 95% confidence interval of the corresponding permu-
tation. The solid circles are the observed values plotted against the permutation values.
(A) The quantile-quantile (QQ) plot with SZ as a binary phenotype. Our results show no obvious inflation of type I error.
(B) The QQ plot with data from all nine factors analyzed together. There are three observations above the 97.5 percentile of the study-
wide permutation data. When those three observations are removed (the result shown in open circles), the distribution shows no evidence
of type I error inflation.
(C) The QQ plot with the ‘‘delusion’’ factor as a quantitative trait. The three observations with highly significant values are the same as
those of (B); removal of those three observations (open circles) yields a distribution that fits the permutation data quite well.for our factor analyses are from the quantitative TDT, case-only
quantitative traits association studies, and combined analyses.
For our strongest association signal, we also conducted tests
with the FBAT38 and QTDT39 software packages to conﬁrm the
validity of our results. With FBAT v1.7.3, we performed 1 3 108
Monte Carlo samplings to calculate an empirical p value. With
QTDT v2.6.0, we used the default orthogonal model described
by Abecasis et al.39
We used PedCheck40 v1.0 to detect Mendelian inconsistencies
and HaploView41 v4.0 to calculate linkage disequilibrium and to
generate graphical representations of the marker-to-marker
disequilibrium and underlying haplotype block structure.
Permutation and Correction for Multiple Testing
We performed 10,000 permutations with UNPHASED for the anal-
ysis of each phenotype and used the results to make the quantile-The Aquantile plots (QQ plots) (Figure 3) and to estimate the study-wide
signiﬁcance level of our results.
We applied two additional strategies for multiple test correction.
For the ﬁrst, we assumed that the genotypes of the 1414 SNPs were
independent and used the Bonferroni method to correct for 1414
tests (‘‘all’’ SNPs). For the second, we took into account the linkage
disequilibrium between nearby SNPs to calculate the number of
independent SNPs (‘‘independent’’ SNPs).42,43 In brief, we consid-
ered SNP genotypes within the same LD block (the criteria used by
Gabriel et al.44) as a single independent test, and we counted
genotypes for SNPs outside of LD blocks individually. These
calculations reduced the number of ‘‘independent’’ tests for
Bonferroni correction to 532. With these strategies, the cut-off
p value for claiming statistical signiﬁcance is either 3.54 3 105
(¼ 0.05/1414, ‘‘all’’ tests) or 9.40 3 105 (¼ 0.05/532, ‘‘indepen-
dent’’ tests). The study-wide cut-off p values for the analysis of(p ¼ 3.93 3 106). The lower horizontal pink line marks the cutoff value for Bonferroni correction of 532 independent SNPs and all
9 factors (p ¼ 1.04 3 105).
(C) Genes and segmental duplications in this region, according to UCSC genome browser with the NCBI genome build 35.1 data.merican Journal of Human Genetics 84, 21–34, January 9, 2009 25
Table 2. 20 SNPs with the Smallest p Values with SZ as the Discrete Phenotype
SNP Name
Position
(Build 35) Gene/Locus
Trios Case-Control Combined
p Value Odds Ratio p Value Odds Ratio p Value Odds Ratio
rs7913285 80228807 8.34 3 102 1.24 (0.98–1.57) 2.99 3 102 1.24 (1.02–1.49) 4.54 3 103 1.28 (1.08–1.51)
rs1013005 80239045 1.76 3 102 1.34 (1.06–1.69) 2.93 3 102 1.23 (1.03–1.47) 2.82 3 103 1.29 (1.09–1.52)
rs10762810 80250777 1.73 3 102 1.35 (1.06–1.72) 1.35 3 102 1.27 (1.06–1.52) 1.86 3 103 1.31 (1.11–0.15)
rs1080293 83886240 NRG3 1.96 3 102 1.44 (1.07–1.93) 8.43 3 103 1.36 (1.08–1.70) 1.04 3 103 1.41 (1.16–1.73)
rs1649967 83897704 NRG3 1.04 3 101 1.25 (0.96–1.61) 4.78 3 102 1.22 (1.00–1.48) 1.52 3 102 1.25 (1.05–1.49)
rs11592457 85145754 2.62 3 102 2.18 (1.05–4.55) 1.48 3 101 1.41 (0.88–2.24) 7.09 3 103 1.79 (1.15–2.78)
rs4244944 85834794 9.84 3 103 1.35 (1.08–1.68) 9.77 3 103 1.27 (1.06–1.53) 1.38 3 102 1.23 (1.04–1.44)
rs4244946 85963245 PCDH21 8.11 3 104 1.39 (1.08–1.78) 7.58 3 102 1.19 (0.98–1.45) 1.47 3 102 1.24 (1.04–1.48)
rs2222546 87652091 GRID1 4.30 3 101 1.10 (0.86–1.41) 1.53 3 102 1.26 (1.04–1.52) 7.86 3 103 1.25 (1.06–1.48)
rs12098567 88063754 GRID1 1.23 3 101 2.00 (0.82–4.86) 5.42 3 103 2.71 (1.30–5.65) 9.71 3 103 2.13 (1.22–3.71)
rs1745903 88742186 KIAA1975 1.39 3 102 1.34 (1.07–1.69) 6.33 3 103 1.29 (1.07–1.56) 5.40 3 103 1.26 (1.08–1.49)
rs12771728 89345293 3.56 3 103 1.49 (1.12–1.97) 9.57 3 102 1.18 (0.97–1.44) 8.08 3 104 1.36 (1.14–1.63)
rs12778872 89346913 2.75 3 102 1.46 (1.02–2.07) 2.03 3 101 1.17 (0.92–1.50) 6.96 3 103 1.36 (1.08–1.72)
rs791888 89402555 1.04 3 102 1.38 (1.08–1.77) 1.73 3 101 1.14 (0.95–1.37) 6.54 3 103 1.26 (1.07–1.50)
rs9630112 89834555 1.38 3 102 1.34 (1.06–1.69) 2.18 3 103 1.33 (1.11–1.59) 9.19 3 104 1.32 (1.12–1.55)
rs4933466 89839499 2.54 3 103 1.43 (1.13–1.82) 3.49 3 102 1.22 (1.02–1.46) 4.23 3 104 1.35 (1.14–1.59)
rs11202656 89856629 4.73 3 103 1.45 (1.11–1.90) 1.90 3 101 1.15 (0.94–1.41) 1.61 3 103 1.35 (1.12–1.63)
rs7922193 91011625 8.61 3 102 1.22 (0.97–1.52) 1.37 3 102 1.26 (1.05–1.50) 1.08 3 102 1.23 (1.05–1.44)
rs10430719 91028961 3.29 3 102 1.40 (1.01–1.95) 3.69 3 102 1.29 (1.01–1.63) 7.69 3 103 1.33 (1.07–1.66)
rs3824603 91333587 PANK1 3.09 3 102 1.35 (1.02–1.79) 4.73 3 102 1.24 (1.00–1.55) 1.10 3 102 1.29 (1.06–1.56)the nine factors were calculated at 3.93 3 106 for ‘‘all’’ tests and
1.04 3 105 for ‘‘independent’’ tests.
Investigation of ‘‘Failed’’ SNPs and Detection
of Copy-Number Variations
Among the 1536 SNPs, 59 were ﬂagged for low quality or Mende-
lian inconsistency and were not used in the ﬁltered data set in our
analysis. We looked at the detailed genotyping results for these
SNPs individually to determine whether their apparent poor
performance could be explained by other than technical reasons.
We considered Mendelian inconsistencies in certain pedigrees as
a possible indication of CNV, such as a deletion, at the correspond-
ing regions. For those SNPs, we then looked at the ‘‘Log R Ratio’’
readings of Illumina genotyping data, which represented the level
of ﬂuorescence probing intensity and provided further evidence of
copy-number difference of the genomic DNA. If necessary, we
used quantitative PCR to conﬁrmCNVs and conducted long-range
PCR and sequencing to demonstrate the boundaries. Several unre-
lated individuals were sequenced for each conﬁrmed CNV to
compare the junction points.
Sequencing
We sequenced known exons and several conserved noncoding
regions of two genes (GRID1 and NRG3) in ampliﬁed products of
the genomic DNA from six AJ normal controls and 15 unrelated
AJ SZ individuals from the original linkage families.22 We also
sequenced presumptive break point fragments to conﬁrm dele-
tions. Sequencing of each PCR product was conducted from
both directions with a capillary DNA sequencer (ABI 3100 Genetic
Analyzer, Applied Biosystems, CA) according to the company-
recommended protocol.
Results
Association Analyses with SZ as a Discrete Phenotype
The results of the allelic test for all 1414 SNPs in family-
based association analysis, case-control analysis, and26 The American Journal of Human Genetics 84, 21–34, January 9, 2combined (all samples together) association study with
SZ affected status as the discrete phenotype are shown in
Figure 2A. The plots comparing the observed versus the ex-
pected at random distribution of p values (QQ plots) show
that the distribution of the majority of p values ﬁts the
prediction of our permutation results, suggesting no gross
inﬂation of type I errors (Figure 3). SNPs with the 20 small-
est p values are listed in Table 2 and results of all SNPs are in
Table S1. None of these SNPs are statistically signiﬁcant
according to either stringent or LD-based Bonferroni
corrections.
Association Analyses with Nine Factors
as Quantitative Traits
The results of our association analyses with factors as the
quantitative trait phenotypes are shown in Figure 2B. For
visual clarity, we overlay the results of nine factors together
without using different symbols for each factor. The
comprehensive results for each individual factor can be
found in Table S2 and a description of the 20 SNPs with
the smallest p values across all nine factors is provided in
Table 3. We observed no gross inﬂation of type I errors
according to the comparison to the permutation results
(Figure 3).
We identiﬁed a strong association signal by using the
‘‘delusion’’ factor as the phenotype. Our primary analysis
(allelic test in 285 trios) with UNPHASED gave the smallest
p values at three consecutive SNPs located in a 13 kb
interval (p ¼ 7.26 3 107 at rs10883866 and rs10748842;
p ¼ 8.40 3 106 at rs6584400). We examined the genotyp-
ing quality of these three SNPs by using Illumina’s Bead-
Studio software and found the results reliable (GenTrain
scores: 0.94, 0.83, and 0.83, respectively; and none of the
three SNPs violates Hardy-Weinberg equilibrium). Two of009
Table 3. 20 SNPs with the Smallest p Values with Each of the Nine Factors as Quantitative Traits
SNP Name
Position
(Build 35)
Gene/
Locus
Trios Cases Combined Factor
Responsible for
the p Valuep Value Effect Sizea p Value Effect Sizea p Value Effect Sizea
rs2019080 79951742 3.92 3 102 0.25
(0.00–0.50)
1.23 3 102 0.17
(0.03–0.31)
8.24 3 104 0.28
(0.11–0.44)
delusion
rs1574190 80662387 RAI17 1.04 3 103 0.43
(0.14–0.72)
7.02 3 104 0.24
(0.10–0.39)
2.02 3 104 0.33
(0.14–0.51)
prodromal
rs4319456 82927110 * 1.11 3 102 0.50
(0.09–0.92)
1.31 3 103 0.35
(0.13–0.57)
5.79 3 104 0.46
(0.20–0.71)
disorganization
rs7899151 82938902 * 1.62 3 103 0.67
(0.22–1.12)
2.01 3 103 0.34
(0.10–0.57)
4.27 3 104 0.48
(0.20–0.76)
disorganization
rs10883866 83633619 NRG3 7.26 3 107 0.97
(0.49–1.45)
5.27 3 106 0.51
(0.28–0.74)
2.30 3 107 0.67
(0.37–0.97)
delusion
rs10748842 83639719 NRG3 7.26 3 107 0.97
(0.49–1.45)
5.27 3 106 0.51
(0.28–0.74)
2.30 3 107 0.67
(0.37–0.97)
delusion
rs6584400 83646506 NRG3 8.40 3 106 0.75
(0.36–1.14)
1.51 3 105 0.44
(0.24–0.64)
1.59 3 106 0.55
(0.30–0.81)
delusion
rs17099528 83921863 NRG3 5.72 3 103 67.2
(4.8–139)
2.94 3 103 1.90
(0.46–3.33)
1.34 3 103 2.53
(0.85–4.22)
disorganization
rs951204 84038745 NRG3 5.46 3 103 0.47
(0.12–0.83)
1.60 3 102 0.23
(0.03–0.43)
1.24 3 103 0.37
(0.13–0.61)
disorganization
rs12416489 84717603 NRG3 4.73 3 102 0.22
(0.00–0.44)
3.78 3 102 0.14
(0.00–0.27)
1.24 3 103 0.25
(0.09–0.41)
scholastic
rs11196700 84724720 NRG3 6.01 3 103 0.32
(0.09–0.54)
1.24 3 102 0.17
(0.03–0.31)
3.42 3 104 0.29
(0.12–0.46)
scholastic
rs3818306 84728393 NRG3 4.73 3 102 0.22
(0.00–0.44)
3.78 3 102 0.14
(0.00–0.27)
1.24 3 103 0.25
(0.09–0.41)
scholastic
rs8421 84736601 NRG3b 6.01 3 103 0.32
(0.09–0.54)
1.20 3 102 0.17
(0.03–0.31)
3.36 3 104 0.29
(0.12–0.45)
scholastic
rs1339844 84856649 NRG3b 3.76 3 103 0.36
(0.09–0.64)
3.15 3 102 0.16
(0.01–0.30)
2.74 3 104 0.32
(0.14–0.49)
scholastic
rs10886221 85123936 * 1.12 3 101 0.22
(0.06–0.50)
7.48 3 102 0.13
(0.02–0.29)
8.94 3 104 0.30
(0.12–0.47)
hallucination
rs12220927 89980527 6.04 3 102 0.28
(0.01–0.56)
8.00 3 103 0.23
(0.07–0.38)
1.45 3 104 0.40
(0.19–0.60)
disability/
impairment
rs4934396 90108138 C10orf59 1.09 3 102 0.61
(0.05–1.18)
6.64 3 103 0.33
(0.07–0.59)
8.50 3 104 0.50
(0.18–0.82)
disorganization
rs11202748 90199318 C10orf59 5.50 3 103 0.42
(0.10–0.74)
2.24 3 102 0.19
(0.02–0.36)
2.76 3 104 0.37
(0.16–0.58)
disorganization
rs10509546 90201633 C10orf59 4.25 3 103 0.53
(0.14–0.92)
2.13 3 102 0.23
(0.03–0.43)
5.77 3 104 0.42
(0.17–0.67)
disorganization
rs10430719 91028961 4.75 3 102 0.32
(0.00–0.63)
2.27 3 102 0.19
(0.01–0.37)
3.33 3 104 0.37
(0.14–0.60)
prodromal
a AddVal values from the UNPHASED output results. For quantitative traits, this value shows the estimated additive genetic value for this risk allele
compared to the nonrisk allele, assuming a normally distributed trait and small deviations from the mean.
b 30 downstream of NRG3, which is within the LD block containing the last 5 exons of NRG3.
* Located in the gene deserts flanking NRG3.these SNPs (rs10883866 and rs10748842) are only 6.1 kb
apart and in complete linkage disequilibrium (r2 ¼ 1) and
thus have the same p values. Hereafter, unless otherwise
speciﬁed, we report the p value(s) for rs10883866 as the
representative for this association signal. The result is
study-wide signiﬁcant, even under the most stringent Bon-
ferroni correction (the study-wide cut-off p value ¼ 3.93 3
106, for 9 quantitative phenotypes and 1414 SNPs). We
performed analyses by QTDT (p ¼ 3.0 3 107) and FBAT
(p ¼ 6.7 3 107) to ensure that the results are robust to
the use of different analytical software packages. Further-
more, association analysis with our 173 independent cases
replicated the signal (p ¼ 1.55 3 102) and pointed to theThe Asame susceptibility allele. The combined p value (with 285
trios and 173 independent cases together) was 2.303 107.
Further analysis with the genotypic test also showed signif-
icant results (family-based analysis, p ¼ 2.63 3 105; 173
independent cases, p ¼ 9.96 3 103; and combined
samples, p ¼ 3.86 3 106). The alleles associated with
higher scores of the delusion factor are the minor
alleles for all three SNPs. Detailed results are summarized
in Table 4.
In addition to theoretical approaches, study-wide signif-
icance level can be empirically estimated with permutation
data. We performed 10,000 permutations for each of the
9 factors, and only in 27 permutations observed p valuesmerican Journal of Human Genetics 84, 21–34, January 9, 2009 27
Table 4. SNPs Strongly Associated with the Delusion Factor
Allelic Test (p Values) Genotypic Test (p Values)
285 Trios
173 Cases,
Independent
458
Cases,
All
1028
Persons,
Combined
285
Trios
173 Cases,
Independent
458
Cases,
All
1028
Persons,
Combined
SNP Name Allele
Risk
Allele
Freq.
of
Risk
Allele UNPHASED FBAT QTDT
rs10883866 C/G G 0.11 7.26 3
107
6.7 3
107
3.0 3
107
1.55 3 102 5.27 3
106
2.30 3
107
2.63 3
105
9.96 3 103 8.36 3
105
3.86 3
106
rs10748842 T/C C 0.11 7.26 3
107
6.7 3
107
3.0 3
107
1.55 3 102 5.27 3
106
2.30 3
107
2.63 3
105
9.96 3 103 8.36 3
105
3.86 3
106
rs6584400 G/A A 0.13 8.40 3
106
1.8 3
105
3.0 3
106
1.97 3 102 1.51 3
105
1.59 3
106
2.29 3
104
5.28 3 102 1.85 3
104
2.36 3
105smaller than 2.30 3 107. Accordingly, we estimate the
empirical study-wide signiﬁcance level for 9 quantitative
traits as p ¼ 2.7 3 103.
The three SNPs with the strongest association with the
delusion factor span a 13 kb region in intron 1 of the
NRG3 gene. LD block structure around NRG3 derived
from our AJ samples does not differ from results of the
CEU samples in the HapMap project (Figure 4). The three
associated SNPs reside in a ~160 kb LD block containing
the promoter, exon 1, and part of intron 1 of NRG3
(Figure 4).
We also observed an excess of association signals in
NRG3 overall. In addition to the three SNPs associated
with the delusion factor, there are seven other SNPs either
in NRG3 or its immediate ﬂanking sequences that ranked
in the top 20 best p value list (Table 3). Moreover, three
other top 20 SNPs are located 388–697 kb outside of
NRG3 in the two ﬂanking gene deserts (Table 3). These
10 additional SNPs are not in LD with the three SNPs asso-
ciated with the delusion factor (data not shown) and
showed association with the scholastic, disorganization,
and hallucination factors but not with delusion factor.
Thus, taken together, 13 of the top 20 SNPs are located
in or around NRG3 and show evidence for association
with 4 of the SZ phenotypic factors.
Identiﬁcation of Two Small Segregating
Deletions in NRG3
As part of our ﬁne mapping experiment, we detected
Mendelian inconsistencies in the genotypes of 19 of the
total 1536 SNPs genotyped. We considered that some of
these might represent copy-number variations and there-
fore focused on regions with consecutive SNPs with
Mendelian inconsistency. We found two regions that ﬁt
these criteria, both within NRG3. The genotyping plots
and intensity data in those families exhibited reduced ﬂuo-
rescence intensity in some family members, compatible
with the presence of segregating deletions. We performed
quantitative PCR (data not shown) for one of the two
regions to conﬁrm and precisely locate the putative dele-28 The American Journal of Human Genetics 84, 21–34, January 9, 2tion. Long-range PCR followed by cloning and sequencing
of the PCR products conﬁrmed and deﬁned the deletion
break points in both regions. The more 50 break point is
a ~5.5 kb deletion (hereafter referred to as D5.5) (starting
at chr10:83,873,517 and ending at chr10:83,879,043)
with an allele frequency of 2.62% in cases and 2.57% in
controls. The more 30 break point is a ~32.2 kb deletion
(hereafter referred to as D32.2) (starting at chr10:
84,524,457 and ending at chr10:84,556,666) with an allele
frequency of 0.88% in cases and 0.72% in controls. We
sequenced ampliﬁed break point fragments from 12 unre-
lated individuals with D5.5 and 2 unrelated individuals
with D32.2, and found the break point for each deletion
to be identical in all samples. In our small sample, we did
not ﬁnd association between these deletions and SZ or
any of the nine factors (data not shown), but our power
to detect association signal for genetic variants with these
frequencies is minimal.
Both of these inherited microdeletions are in NRG3;
deletion D5.5 is in intron 1 and deletion D32.2 is in intron
3 (Figure 4). Deletion D32.2 includes an alternative non-
coding ﬁrst exon of NRG3, which is annotated in a human
mRNA clone (AK098823)45 and conﬁrmed by our RT-PCR
experiment (data not shown).
Discussion
We conducted a peak-wide association ﬁne mapping of
a 12.5 Mb region on 10q22-q23 in the AJ population,
a region identiﬁed in our previous genome-wide linkage
analysis of SZ in the AJ.22 In addition to the binary pheno-
type of SZ, we tested nine quantitative trait phenotypes
derived from principal components factor analysis. By
using 285 parent-child trios, we found that a ~13 kb region
containing three SNPs in the 50 region of NRG3 showed
strong evidence of association with the ‘‘delusion’’ factor
at a study-wide signiﬁcance level. We replicated this as-
sociation signal by using 173 unrelated SZ individuals.
We also found multiple weaker association signals in other
segments of NRG3 as well as two small deletions, one of009
Figure 4. Results of Association Analyses and Selected Genomic Features in and around NRG3
(A) Association analysis results (combined samples) with SZ as the binary phenotype and three factors (scholastic, delusion, and disor-
ganization) as quantitative traits. As in Figure 2, the two short upper horizontal pink lines represent the study-wide significance cut-off
p values (either for all SNPs, higher, or for independent SNPs, lower) for all nine factors. The long horizontal pink line (p ¼ 1.343 103)
marks the 20th smallest p value from all 1414 SNPs of the ~12.5 Mb region with any of the nine factors as the phenotype. We also plot the
two segregating deletions (solid rectangles) and the three SNPs (and two flanking SNPs) with the most significant associations. We also
provide the NRG3 gene and the LD block structure (based on r2 values) for the CEPH (CEU) from the HapMap project and the LD block
structure for the AJ population from 487 controls of our current study to show the relative positions of these association results.
(B) A closer look at the 50 region of NRG3. The p values of the same three SNPs (and two flanking SNPs) are indicated.which removes an alternative, ﬁrst noncoding exon of
NRG3.
Challenges for Identifying SZ Susceptibility Genes
Genetic heterogeneity, including both allelic and locus
heterogeneity, is one of several challenges for discovery
of genes and alleles contributing to human disease pheno-
types. To minimize heterogeneity, we conducted our studyThe Aonly in the AJ population, where founder effects have been
reported for both monogenic diseases and complex
traits,46–50 and LD structure has shown this group to be
somewhat more homogeneous than the outbred northern
European population.51 A second challenge is phenotypic
misclassiﬁcation. To deal with this, we established a
rigorous assessment protocol that included tape-recorded
interviews performed by skilled diagnosticians andmerican Journal of Human Genetics 84, 21–34, January 9, 2009 29
reviewed independently by two members of a consensus
diagnosis committee.22 A third challenge involves the
complexity of the SZ phenotypes; for example, these
include positive and negative symptoms likely reﬂecting
different central nervous system (CNS) dysfunctions that
are not adequately described by a binary variable (SZ,
yes/no).13,14 To account for this complexity, we incorpo-
rated more extensive phenotypic information (73 items
from the consensus ratings and direct assessment inter-
views) and used principal components analysis to identify
nine independent factors to serve as quantitative pheno-
types in our analyses.
SZ as the Discrete Phenotype
When SZ was used as the discrete phenotype, several SNPs
had nominal p values reaching the 0.05 signiﬁcance level,
but none reached our multiple test correction thresholds.
The association signal in intron 2 of GRID1 previously re-
ported by our group in a candidate gene-based study25 per-
sisted in this current analysis at about the same level of
signiﬁcance (p ¼ ~0.01). This was not sufﬁciently strong
to be reliably detected in our current analyses. Intriguingly,
GRID1 recently has also been implicated as a SZ suscepti-
bility gene in a case-control study (260 cases and 307
controls) in a Northern Han Chinese sample, with the
most signiﬁcant nominal p value of 1.1 3 105
(rs11591408, near exon 2).26 We did not genotype
rs11591408 in this study and there is no information
about the linkage disequilibrium or allele frequency of
this SNP in the public databases. To summarize, by using
SZ as a discrete phenotype, we found some nominally
signiﬁcant associations but none strong enough to with-
stand rigorous correction for multiple testing. We list our
best results in Table 2 for future testing in independent
samples.
Assuming validity of our linkage result, there are
multiple reasons for failing to ﬁnd an association signal
for genuine susceptibility variants, including multiple
causative genes in the same linkage interval; multiple
(rare) responsible alleles in a single gene;52 interactions
between genes/alleles; insufﬁcient power; inability of
regular SNP genotypes to represent the information of
causative genetic variants (such as CNVs or inversions);
inadequate marker coverage; genetic heterogeneity; and
phenotypic heterogeneity. Despite the lack of signiﬁcant
association with the diagnosis of SZ, our results are useful
for comparison with other studies and will allow for unbi-
ased meta-analyses.
Nine Factors as the Quantitative Trait Phenotypes
It has long been argued that schizophrenia is not a nosolog-
ical monolith but rather a heterogeneous collection of
related phenotypes.12,14 The importance of careful delinea-
tion of phenotypes of diseases with genetic heterogeneity
has been well addressed.53,54 To this end, we tested nine
symptom factors as the quantitative phenotypes for our
association study, with the expectation that these factors30 The American Journal of Human Genetics 84, 21–34, January 9, 2would provide more homogeneous and meaningful
phenotypes for genetic analysis. In practice, this approach
comes at the price of increasing the number of hypotheses
tested.
With this approach, we identiﬁed a strong association at
the 50 region of NRG3 by using the ‘‘delusion’’ factor as the
quantitative trait phenotype. The primary analysis (allelic
test in 285 parent-child trios) yielded a signiﬁcant p value
(p ¼ 7.26 3 107) that can sustain the most stringent
study-wide Bonferroni correction for 9 quantitative
phenotypes and 1414 SNPs. Most importantly, this associ-
ation signal was replicated in our sample of 173 indepen-
dent, unrelated SZ individuals of AJ descent. Analyses
with combined family samples and independent cases
yielded an even stronger signal (p ¼ 2.30 3 107). Geno-
typic tests provided similar results (Table 4). We estimated
the study-wide signiﬁcance level to be p ¼ 2.73 103 after
10,000 permutations.
We found several additional association signals in and
around NRG3 (Figure 4). Including the 50 and 30 LD blocks
extending from both ends,NRG3 spans a ~1.5Mb genomic
region, or about 12% of the 12.5 Mb region we covered in
our ﬁnemapping study (13.1%, if we exclude the ~1.06Mb
duplicated regions poorly covered by the SNPs we geno-
typed). Stimulated by our results implicating NRG3, we
asked whether any other SNPs among our 20 most signiﬁ-
cant signals across all factors supported involvement of
NRG3. The list of the 20 SNPs with the smallest p values
in our factor analysis includes a total of 10 (50%) SNPs in
NRG3. In addition to the 3 SNPs associated with the delu-
sion factor, there are 7 SNPs that demonstrate suggestive
evidence of association with 2 other factors (scholastic
and disorganization). There are 3 more SNPs on the top
20 list located in the gene deserts ﬂanking NRG3 (Table 3).
The SNPs responsible for these different factor associations
are not in LD with each of the others (data not shown).
Although the association signals for these additional 10
SNPs fail to withstand multiple test correction, in aggre-
gate this result is consistent with multiple causative vari-
ants in different regions of the NRG3 gene. Allelic hetero-
geneity is the rule in rare disorders and has also been
observed in various common traits.55–59 The highly signif-
icant result for the delusion factor together with the
multiple nominal associations with other factors strongly
suggests that, in our population, multiple alleles of NRG3
play an important role in SZ. The biological basis of this
effect could be the result of multiple alleles inﬂuencing
the risk for SZ, each with some distinct genotype-pheno-
type correlation, or it could be that NRG3 variants inﬂu-
ence the phenotypic features manifested by individuals
who have SZ because of a constellation of other genetic
and environmental variables. Determining between these
or other possibilities will require identiﬁcation of the caus-
ative variants, elucidation of their functional conse-
quences on NRG3 or other genes, and a better under-
standing of the biological functions of NRG3 and its
multiple spliceforms.009
We obtained a 9 factor solution based on 73 items
(Table 1) of the consensus ratings and direct assessment
interviews. This number of factors is larger than identiﬁed
in other analyses of SZ in part because we scored a larger
number of items including those that may reﬂect develop-
mental problems and premorbid features. Each factor has
a measurable heritability in our population ranging from
0.27 to 0.61, and each factor is independent of the other
eight.28 Many of the factors, such as the delusion, nega-
tive, disorganization, hallucination, and affective, have
been derived in similar forms in other studies of SZ.60–62
It is noteworthy that the ‘‘delusion’’ factor which has the
most prominent association signal in our analysis is
roughly equivalent to the classic Schneiderian ‘‘ﬁrst-
rank’’ symptoms,63 or ‘‘nuclear syndrome’’ factors in other
studies, where sib-pair correlations have been demon-
strated.64,65 These ﬁrst-rank symptoms have been given
particular weight for making diagnosis of SZ and might
be expected to have etiological signiﬁcance.64,65
Identiﬁcation of NRG3 Microdeletions
CNVs, including small deletions, are plausible disease-
causing variants that are easily overlooked but can be iden-
tiﬁed by careful analysis of SNP genotyping data. Taking
advantage of the inheritance information in our family
sample, genotype information, and intensity variation of
SNP calls, we discovered, conﬁrmed, and precisely delin-
eated two novel microdeletions inNRG3. Although neither
of the deletions we identiﬁed showed association with SZ
or any of the nine factors, our power to detect association
signal for genetic variants of such low frequencies was
limited. Intriguingly, the D5.5 deletion is in intron 1 where
we ﬁnd an association signal, and the D32.2 deletion in
intron 3 removes an alternative, ﬁrst noncoding exon of
NRG3. In future studies, it will be important to investigate
the potential impact of these CNVs on the expression and
function of NRG3.
Analogy of the Association Signal forNRG1 andNRG3
Associations of variants in NRG1 with SZ have been repli-
cated by several groups.66,67 NRG3 is a paralog of NRG1
with an expression pattern that is more limited to the
CNS68 and, like NRG1, encodes a single-pass membrane
protein with an N-terminal EGF domain on the extracel-
lular side of the plasma membrane. When we designed
our SNP ﬁne mapping project as an unbiased approach,
we selected SNPs to evenly cover the whole ~12.5 Mb
region without taking into account the location of known
genes (see Subjects and Methods). It is intriguing that our
best association signal mapped to a LD block at the 50
end of NRG3, analogous to the results implicating NRG1.66
NRG1 spans a ~1.25Mb genomic region, with a large ﬁrst
intron and a ~300 kb LD block containing the promoter,
exon 1, and part of the intron 1. The initial study impli-
cating NRG1 as a SZ susceptibility gene showed association
to a risk haplotype located at the 50 end of the gene.66
Several studies have replicated the association signal, andThe Aalmost all of the published risk SNPs/haplotypes in
northern Europeans were mapped to the 50 end of
NRG1.67 Recently, an alternative NRG1 ﬁrst exon, 479
base-pairs upstream of the standard exon 1 and also con-
tained in the 50 LD block, was identiﬁed and shown to be
transcribed only in the CNS. Increased levels of this CNS-
speciﬁc NRG1 transcript in human postmortem hippo-
campus were shown to be associated with the SNP risk
allele for SZ.69–71 How these susceptibility SNPs/haplo-
types at the 50 end of NRG1 lead to functional changes in
NRG1 isoforms is currently under vigorous investigation.
The NRG3 gene spans a ~1.2 Mb genomic region and,
like NRG1, has a large ﬁrst intron and a large 50 LD block
(~160 kb) containing the promoter, exon 1, and part of
the intron 1. The association signal we report here is at
the 50 end of intron 1 within 10 kb of exon 1. An alterna-
tive transcription start site, located between the original
exon 1 and the association signal we report here, has
been identiﬁed in human fetal brain and produces a
neural-speciﬁc NRG3 transcript capable of affecting oligo-
dendrocyte survival in vitro.72 Additionally, there are
several potentially functional elements in and around
the region of our best association signal that could harbor
susceptibility variants affecting NRG3 expression or func-
tion, including the proximal promoter, exon 1, alternative
transcription start site(s), possible alternative exons, and
conserved noncoding elements. We sequenced all the
exons and axon-intron junction regions in 15 unrelated
AJ SZ probands from our original linkage pedigrees22 and
found no sequence variants that could obviously alter
NRG3 function (data not shown). It will be important to
conduct more comprehensive sequencing of NRG3 in the
future. Studies to clarify the transcription proﬁle and func-
tion of NRG3 are also warranted.
Although little has been published regarding NRG3, its
function shares some common pathways with NRG1 in
the central nervous system. The full-length human NRG3
protein, 720 amino acids in length, has an extracellular
EGF-like domain (31% identity with the NRG1 EGF-like
domain) that has been shown to be functional.68,72 The
only known binding receptor for NRG3 is erbB4, although
NRG1 binds to both erbB3 and erbB4.73,74 SZ-related traits
were observed in various genetically modiﬁed mice with
mutation of Nrg1 or erbB4 (but not erbB3).75 A recent asso-
ciation analysis reported suggestive evidence of interaction
between NRG1 and NRG3 on their effect of SZ suscepti-
bility.27 During the preparation of this manuscript,
a genome-wide association study of SZ in an Israeli AJ
sample was published.76 Although the focus of this report
was on an association of a variant in RELN limited to
females with SZ, we note that the 206th best SNP (the top
0.04%) out of 510,552 genotyped in the overall sample
and the 11th best (the top 0.002%) in the male sample
was rs17559044. This SNP is located in intron 1 of NRG3,
228.9 kb 30 from our strongest association signal for the
delusion factor and 23.7 kb 50 from our best association
signal for the diagnosis of SZ in NRG3. We could ﬁnd nomerican Journal of Human Genetics 84, 21–34, January 9, 2009 31
evidence for an effect of sex on our signal. While this
manuscript was being revised, Wang et al.77 reported asso-
ciation of SZ in a Han Chinese population in Taiwan with
two SNPs (rs1937970 and rs677221) located in intron 2 of
NRG3, approximately 0.6 Mb telomeric of our peak signal.
These two SNPs were genotyped in our study and did not
show signiﬁcant association in our samples (Tables S1
and S2).
In summary, we performed SNP ﬁne mapping of SZ and
related phenotypes at our previous linkage peak. With the
‘‘delusion’’ factor as quantitative trait phenotype, we
found a strong association signal at the 50 end of NRG3
when analyzing 285 parent-child trios, and we subse-
quently replicated the signal with 173 independent SZ
individuals. Our results suggest that NRG3 inﬂuences the
SZ risk and presentation in multiple ways, the clariﬁcation
of which requires further investigation. The analogy with
NRG1 results and the location of possible NRG3 functional
elements in and around the implicated risk region support
our conclusion that alleles of NRG3 play a role in the
etiology and/or phenotypic manifestation of SZ. Further
efforts to replicate the association result with other inde-
pendent samples, to sequence the 50 end region with
reasonable coverage, to clarify the transcription proﬁle,
and to study the function of NRG3 are warranted.
Supplemental Data
Supplemental Data include two tables and can be found with this
article online at http://www.ajhg.org/.
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